Salt Lake City, United States and Kyiv, Ukraine – [April 8, 2025] — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world’s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized compounds designed to accelerate drug discovery against the hundred most difficult to address biological areas and clinically relevant key drug targets.
Enamine’s REAL Space represents the continuously expanding chemical library built on insights from millions of parallel syntheses. While the chemical space offers incredible potential, the sheer volume of compounds, numbering in the tens of billions, makes it difficult to select the most promising candidates. By combining the expansive REAL Space with the Recursion OS to predict small molecule compatibility with protein targets, the collaboration allows for the creation of smaller, highly focused libraries that outperform traditional high-throughput screening (HTS) collections.
We have been using the Recursion OS to identify compounds across Enamine’s vast chemical space for our own internal discovery needs,
said Chris Gibson Co-Founder and CEO of Recursion. This collaboration allows us to extend that approach to areas of biology that are of general interest to the industry. We are bringing together the best of both worlds—Enamine’s vast chemical library and Recursion’s AI-driven drug discovery platform to help expand the drug discovery toolset.
These curated compound libraries are an output of a research collaboration between Recursion and Enamine, whereby Recursion gained access to tens of thousands of compounds that it individually predicted may interact with the functional areas of biology not addressed by its current 1.2M compound library in exchange for helping to develop libraries of broad commercial interest.
Enamine’s REAL has enormous discovery opportunities. While it has previously been utilized in ultra-large virtual screening campaigns, it has never been explored at scale across multiple targets. Our partnership with Recursion allows us to tap into their cutting-edge technology to rapidly uncover novel compounds with high potential in various research fields rapidly. We are ready to launch this new generation of compound libraries to support our customers’ hit-finding campaigns, secured by rapid access to analogues from REAL,
added Andrey Tolmachov, CEO and Founder of Enamine.
For more information about the curated compound libraries, visit Enamine’s website here: https://enamine.net/compound-libraries